Endo Fha Short Term Transdermal E2 Progestin

---
name: endo-fha-short-term-transdermal-e2-progestin
description: This skill recommends a short course of transdermal estradiol combined with cyclic oral progestin (not oral contraceptives) for adolescents and women with functional hypothalamic amenorrhea who have not resumed menses after a reasonable trial of nutritional, psychological, and/or modified exercise interventions. It is triggered when a clinician states, 'She’s tried diet and CBT but still no periods—let’s try transdermal E2,' or similar phrases such as 'Consider transdermal estrogen after lifestyle changes' or 'Use patch estrogen with progestin for a limited time'.
---

# Short-term transdermal estradiol with cyclic oral progestin after lifestyle trial

## STEP 1 — Gather Information
Collect: confirmation of FHA diagnosis after exclusion of organic causes, duration of amenorrhea (≥3 months or persistent >45-day cycles), details of prior lifestyle interventions (nutritional rehabilitation, CBT, modified exercise), current weight/BMI, bone health status if available, labs: low/low-normal E2 (<20 pg/mL), low/low-normal progesterone (<1 ng/mL), normal or low LH/FSH, normal TSH/prolactin, negative pregnancy test.

## STEP 2 — Rule In / Rule Out
Rule in: patient has FHA (excluded pregnancy, anatomic/pathologic causes, thyroid/prolactin abnormalities) and has failed a reasonable trial of nutritional, psychological, and/or modified exercise interventions (e.g., weight gain, CBT, reduced exercise) without return of menses. Rule out: pregnancy, outflow tract obstruction, ovarian insufficiency (high FSH/LH), hyperprolactinemia, thyroid disease, androgen excess (PCOS), or ongoing severe energy deficit that would make estrogen unsafe (if still catabolic). If any rule-out present, do not proceed; address underlying issue first.

## STEP 3 — Classify or Stratify
If patient meets criteria for short-term transdermal E2 with cyclic progestin: adolescent or adult woman with FHA, failed lifestyle trial, no contraindications (no active eating disorder with ongoing weight loss, no uncontrolled psychiatric illness, no thromboembolic risk, no estrogen-sensitive malignancy). Stratify by bone density: if baseline DXA Z-score ≤ -2.0, consider earlier initiation; if Z-score > -1.0, may still use but monitor.

## STEP 4 — Decide
Prescribe transdermal estradiol (e.g., 100 µg 17β-estradiol patch twice weekly) combined with cyclic oral progestin (e.g., medroxyprogesterone acetate 2.5–5 mg daily for 10–14 days per month) for a limited duration (typically 6–12 months). Reassess every 3 months for return of spontaneous menses, adverse effects, and continued need; discontinue if menses resume or if no improvement after 6–12 months.

## Clinical Guardrails / Mimics / Pitfalls
Do not use oral contraceptives for the sole purpose of regaining menses or improving BMD; they may mask return of spontaneous menses and do not improve bone outcomes. Avoid if patient continues severe energy deficit (ongoing weight loss, restrictive eating) as estrogen may not be effective and could increase thrombotic risk. Monitor for signs of estrogen excess (breast tenderness, nausea) and ensure progestin is cyclic to prevent endometrial hyperplasia. Do not exceed 12–18 months without re-evaluation; long-term use not established for bone benefit in FHA. Mimics: PCOS (high LH/FSH, androgen signs), hyperprolactinemia, outflow tract obstruction (no withdrawal bleed on progestin challenge).

## Concrete Clinical Example
A 16‑year‑old gymnast presents with 8 months of amenorrhea despite 3 months of increased caloric intake and weekly CBT; weight is 90% ideal, BMI 18.2, E2 12 pg/mL, LH 4 mIU/mL, FSH 5 mIU/mL, TSH normal, prolactin normal, pregnancy negative. After confirming failed lifestyle trial, start transdermal estradiol 100 µg patch twice weekly plus medroxyprogesterone acetate 5 mg daily for 12 days each month. At 4‑month follow‑up, she reports light spotting; continue another 4 months, then menses resume spontaneously.

**Source:** Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, https://doi.org/10.1210/jc.2017-00131